Wang Y, Zhou Y, Yang L, Lei L, He B, Cao J et al. Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy. Advanced Science 2023. 来源: 生物制品圈 2024-01-02
Wang Y, Zhou Y, Yang L, Lei L, He B, Cao J et al. Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy. Advanced Science 2023. ! 请注明:姓名+研究方向! 版 权 声 明 本公众号所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,不希望被...
PD-L1表达是目前研究最多且证据较充分的疗效预测标志物。最近发表在Cells杂志(IF=4.366)的一篇综述“Tumour PD-L1 Expression in Small-Cell Lung Cancer: A SystematicReview and Meta-Analysis”首次对SCLC中PD-L1的表达进行了全面的荟萃分析。 研究方法 本次系统评价和荟萃分析通过检索电子数据库(PubMed、Google ...
PD-L1表达是目前研究最多且证据较充分的疗效预测标志物。最近发表在Cells杂志(IF=4.366)的一篇综述“Tumour PD-L1 Expression in Small-Cell Lung Cancer: A SystematicReview and Meta-Analysis”首次对SCLC中PD-L1的表达进行了全面的荟萃分析。 研...
[15] Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications[J]. Chin J Cancer Res, 2014, 26(1): 104-111. [16] Amatatsu M, Arigami T, Uenosono Y, et al. Programmed death-ligand 1 is a promisi...
Nobin H, Garvin S, Hagman H, Nodin B, Jirström K, Brunnström H. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types. BMC Cancer. 2024 Aug 26;24(1):1051. doi...
PD-L1 Expression in Kidney CancerDavid F. McDermott, MD
Although many studies have addressed the prognostic value of programmed cell death-ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic search of the PubMed, EMBASE, and Cochrane Library databases was performed to id
The prognostic value of PD-L1 expression in lung cancer, colorectal cancer, and melanoma is controversial. Blocking antibodies that target PD-1 and PD-L1 have achieved remarkable response rates in cancer patients who have PD-L1-overexpressing tumors. However, using PD-L1 as an exclusive ...
[2]Yan Y, Zheng L, Du Q, et al. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells[J]. Cancer Immunology, Immunotherapy, 2020, 69: 1891-1903. 本文作者丨谭硕